FibroBiologics Inc. (NASDAQ:FBLG) Given Consensus Rating of “Buy” by Analysts

FibroBiologics Inc. (NASDAQ:FBLG) has been given a consensus rating of “Buy” by the five research firms that are presently covering the company, MarketBeat.com reports. Four equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is $13.00.

Separately, D. Boral Capital reissued a “buy” rating and set a $16.00 price target on shares of FibroBiologics in a report on Monday.

FibroBiologics Stock Performance

NASDAQ:FBLG opened at $0.61 on Tuesday. The stock has a 50-day simple moving average of $0.72 and a two-hundred day simple moving average of $1.01. FibroBiologics has a 52-week low of $0.58 and a 52-week high of $4.72. The firm has a market capitalization of $24.15 million, a PE ratio of -1.69 and a beta of -0.74.

FibroBiologics (NASDAQ:FBLG) last released its quarterly earnings results on Thursday, July 31st. The company reported ($0.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.01). Equities analysts forecast that FibroBiologics will post -0.53 earnings per share for the current fiscal year.

Hedge Funds Weigh In On FibroBiologics

A number of hedge funds have recently made changes to their positions in FBLG. Y Intercept Hong Kong Ltd bought a new position in shares of FibroBiologics in the second quarter worth about $37,000. Jane Street Group LLC boosted its stake in shares of FibroBiologics by 415.3% in the fourth quarter. Jane Street Group LLC now owns 61,074 shares of the company’s stock worth $122,000 after acquiring an additional 49,222 shares during the period. O Shaughnessy Asset Management LLC bought a new position in shares of FibroBiologics in the fourth quarter worth about $81,000. Nuveen LLC bought a new position in shares of FibroBiologics in the first quarter worth about $31,000. Finally, AQR Capital Management LLC bought a new position in shares of FibroBiologics in the first quarter worth about $29,000.

FibroBiologics Company Profile

FibroBiologics, Inc operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer.